227 results about "Nanomedicine" patented technology

Provided herein is a method for manipulating the surface density of functional molecules conjugated to nanoparticles, which method including incubating nanoparticles with nucleotides to form nucleotide-coated nanoparticles, adjusting buffer and salt concentration of the conjugation media, adding thiolated molecules in the conjugation media to incubate with the nucleotie-coated nanoparticles, and adding thiolated oligo(ethylene glycol) in the conjugation media to cease the conjugation process of thiolated molecules to nanoparticles. The method is simple, efficient and cost effective, and the surface density of functional molecules can be quickly manipulated in a wide range for various applications, such as biosensing, molecular diagnostics, nanomedicine, and nano-assembly.

The present invention relates to a nano co-delivery system for co-delivering a NO donor and nanomedicine. The system comprises a nanocarrier, the NO donor and the nanomedicine, wherein the nanocarrieris a mesoporous silica nanoparticle, the NO donor is nitrosothiol bonded to the surface of the nanocarrier, and the nanomedicine is loaded in a mesoporous channel of the nanocarrier. The invention also relates to a preparation method of the co-delivery system and application of the co-delivery system in promoting deep permeation of the nanomedicine in tumor tissue. After intravenous administration, the nano co-delivery system is gathered in the tumor tissue through an EPR effect, nitrosothiol is decomposed to release NO, the expression and activity of MMP are improved through a process of NO,ONOO and MMP, tumor matrix collagen is degraded, the deep permeation of the nanomedicine in the tumor tissue is promoted, and an anti-tumor curative effect is improved.

The present invention relates to targeted nanocarriers - also termed nanomedicines - and methods of preferentially, or actively, targeting and delivering a tool for gene transfer or genome editing (i.e., a plasmid or a restriction enzyme - such as a zinc finger nuclease, a CRISPR / Cas system, or a TALEN) or a tool for gene silencing or post-transcriptional regulation of gene expression (i.e., a microRNA, a siRNA, a mRNA, an antisense oligonucleotide, or a sense oligonucleotide) to a range of mammalian cell species. Cell- specific targeting is achieved by using nanocarriers featuring suitable targeting anchors having a targeting moiety that can be a carbohydrate, an antibody or an antibody fragment, a non-antibody protein derivative, an aptamer, a lipoprotein or a fragment thereof, a peptidoglycan, a lipopolysaccharide or a fragment thereof, or a CpG DNA. Such targeting anchors may or may not include a polymeric spacer like polyethylene glycol. The nanomedicines shall allow to therapeutically address a range of mammalian disease entities via various application routes. These indications include malignant diseases, autoimmune diseases, inherited disorders, metabolic disorders, or infectious diseases.